BIOVIE INC.

Overview

Compare with another stock.

• TickerBIVI on Nasdaq¹
• IndustryPharmaceutical Preparations¹
• HeadquartersCarson City, Nevada¹
• Incorporated inNV³
• Business address680 W Nye Lane, Suite 201, Carson City, Nv 89703³
• Filer categoryNon-accelerated filer, Smaller reporting company³
• Legal formCorporation

See how the biggest companies compare on our leaderboards

PD, and approximately 20 million adults in the US suffering from Long COVID, with millions more affected worldwide.⁴ From its latest annual report

Corporate structure

BIOVIE INC. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What BIOVIE INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Intangibles and goodwill

Properties, in its own words

The Company pays an annual rent of $2,200 for its headquarters at 680 W Nye Lane, Suite 201, Carson City Nevada 89703. The rental agreement was for a one-year term, that commenced on October 1, 2022, and was subsequently renewed at each annual maturity date at the same rate.

The Company’s San Diego office lease at 5090 Shoreham Place Suite 206, San Diego, CA 92122 was amended on February 12, 2024 for a larger space. The current monthly base rate for the office space is $10,375, with an annual increase of four percent. The term for the office lease is 60 months.

Item 2 of the 10-K filed Aug 13, 2026.⁴

Leadership

Who has led BIOVIE INC., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerCuong Do V. Sep 16, 2021 to now¹³
• PresidentCuong Do V. Sep 16, 2021 to now¹³
• Chief financial officerR. Richard Wieland Sep 4, 2018 to Sep 4, 2018¹⁴

Named in SEC Form D filings

People the company listed in its private-offering notices.

• Chief Financial Officer and SecretaryJoanne Wendy Kim named Jul 25, 2022³¹
• DirectorJim S. Lang named Jul 25, 2022³¹
• DirectorRichard J. Berman named Jul 25, 2022³¹
• DirectorRobert J. Hariri, M.D., Ph.D. named Jul 25, 2022³¹

Former names

• NANOANTIBIOTICS, INC.Jul 2, 2013 to Jul 22, 2016³

Timeline

1. Sep 14, 20268-K Entered a material agreement³²
2. Aug 6, 20268-K Regulation FD disclosure³³
3. Nov 13, 20258-K Executive or director change³⁴
4. Nov 12, 20258-K Shareholder vote³⁵
5. Aug 11, 20258-K Entered a material agreement; Unregistered sale of shares; Regulation FD disclosure³⁶
6. Jul 23, 20258-K Executive or director change; Regulation FD disclosure³⁷
7. Jun 27, 20258-K Change to shareholders' rights³⁸
8. Jun 24, 20258-K Shareholder vote³⁹
9. Mar 28, 20258-K Executive or director change⁴⁰
10. Nov 8, 20248-K Shareholder vote⁴¹
11. Oct 29, 20248-K Entered a material agreement; Unregistered sale of shares; Regulation FD disclosure⁴²
12. Oct 29, 20248-K Regulation FD disclosure; Other events⁴³
13. Sep 16, 2021New chief executive Cuong Do V. becomes CEO¹³

Calendar

Coming up

1. Nov 9, 2026Reports results for the quarter ending Sep/2026⁴⁴

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

258 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 54 major events, 80 insider forms, 13 large holders, 1 private raises, 90 other. The latest 20:

1. Sep 28, 2026DEF 14A EDGAR
2. Sep 14, 20268-K CURRENT REPORT EDGAR
3. Sep 14, 2026424B5 EDGAR
4. Sep 3, 2026SCHEDULE 13G EDGAR
5. Aug 28, 20264 EDGAR
6. Aug 28, 20264 EDGAR
7. Aug 28, 20264 EDGAR
8. Aug 28, 20264 EDGAR
9. Aug 19, 2026SCHEDULE 13G EDGAR
10. Aug 14, 2026S-1/A FORM S-1 AMENDMENT NO.3 EDGAR
11. Aug 13, 202610-K FORM 10-K FOR PERIOD ENDED JUNE 30, 2026 EDGAR
12. Aug 7, 2026FWP FREE WRITING PROSPECTUS EDGAR
13. Aug 7, 2026SCHEDULE 13G/A EDGAR
14. Aug 7, 2026SCHEDULE 13G EDGAR
15. Aug 6, 2026FWP FREE WRITING PROSPECTUS EDGAR
16. Aug 6, 2026FWP FREE WRITING PROSPECTUS EDGAR
17. Aug 6, 2026S-1/A FORM S-1 AMENDMENT NO. 2 EDGAR
18. Aug 6, 20268-K CURRENT REPORT EDGAR
19. Jul 31, 2026S-1/A FORM S-1 AMENDMENT NO. 1 EDGAR
20. Jul 17, 2026S-1 FORM S-1 REGISTRATION STATEMENT EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

15 open-market trades by officers, directors and large owners since October 2021: 8 buys and 7 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• JANE STREET GROUP, LLCSCHEDULE 13G, 1 filing Sep 3, 2026⁴⁵
• Alta Partners LLCSCHEDULE 13G, 1 filing Aug 19, 2026⁴⁶
• Morgan StanleySCHEDULE 13G/A, 2 filings Aug 7, 2026⁴⁷
• Cuong Do V.SCHEDULE 13D, 1 filing Mar 25, 2026⁴⁸
• Acuitas Group Holdings, LLCSCHEDULE 13D/A, 6 filings Jul 15, 2022 to Jun 30, 2025⁴⁹
• 3i, LPSCHEDULE 13G/A, 2 filings Oct 25, 2024 to Feb 11, 2025⁵⁰

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

1. Jul 15, 2022Raised $6 million in a private offering of equity³¹ Form D: 1 investor so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 36. Change is in shares since the quarter before.

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How BIOVIE INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARBIOVIE INC.¹
• CIK0001580149
• Employer ID (EIN)46-2510769⁴
• Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company⁴
• Incorporated inNevada⁴
• Fiscal year endsJune 30¹
• Industry code (SIC)2834 Pharmaceutical Preparations¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business address680 W Nye Lane, Suite 201, Carson City, NV 89703¹
• Phone775-888-3162¹
• Shares outstanding7,542,638 shares as of Aug 10, 2026⁴
• Public float$8.5M as of Dec 31, 2025⁴
• AuditorEisnerAmper LLP, Iselin PCAOB ID 274; no auditor attestation of internal control over financial reporting⁴
• On EDGAR sinceJul 2, 2013¹
• Filings504 in all: 4 (113), 8-K (88), 10-Q (39), CORRESP (28), S-1/A (25), UPLOAD (20), 3 (19), 424B5 (18)¹
  All 53 form types

  10-K (13), 5 (13), EFFECT (11), SC 13D/A (10), DEF 14A (9), 424B3 (7), 8-K/A (7), S-1 (7), D (6), PRE 14C (5), CERT (4), FWP (4), NT 10-Q (4), PRE 14A (4), S-3 (4), 144 (3), 8-A12B (3), DEF 14C (3), RW (3), S-8 (3), SCHEDULE 13G (3), DRS (2), NT 10-K (2), POS AM (2), SCHEDULE 13G/A (2), 1-A (1), 10-K/A (1), 10-Q/A (1), 424B4 (1), 8-A12B/A (1), 8-A12G (1), AW (1), DEFA14A (1), DEFM14C (1), DRSLTR (1), POS EX (1), PREM14C (1), PRER14A (1), PRER14C (1), RW WD (1), S-1MEF (1), SC 13D (1), SC 13G (1), SCHEDULE 13D (1), SCHEDULE 13D/A (1)

• Latest filingsAnnual report (10-K) Aug 13, 2026
  Quarterly report (10-Q) May 11, 2026
  Proxy statement (DEF 14A) Sep 28, 2026
  Latest 8-K (8-K) Sep 14, 2026

Securities registered for trading

From the cover page of the 10-K filed Aug 13, 2026 (Section 12(b) of the Exchange Act).⁴

Risk factors and legal proceedings

The risks BIOVIE INC. names in Item 1A of its 10-K filed Aug 13, 2026: 47 risks under these headings, as written.⁴

• Risks Relating to Our Business and Industry
• Risks Relating to Our Intellectual Property
• Risks Relating to Our Common Stock
• We rely and will continue to rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines or do not successfully perform and comply with regulatory requirements, we may not be able to obtain regulatory approval of or commercialize our product candidates.
• Successful development of biopharmaceuticals is highly uncertain and is dependent on numerous factors, many of which are beyond our control.
• The concentration of our assets within a certain financial institution could have a material adverse effect on its business, financial condition and results of operations.
• We are currently subject to securities class action litigation and may be subject to similar or other litigation in the future, all of which will require significant management time and attention, result in significant legal expenses and may result in unfavorable outcomes, which may have a material adverse effect on our business, operating results and financial condition, and negatively affect the price of our Common Stock.
• We have no products approved for commercial sale, have never generated any revenues and may never achieve revenues or profitability, which could cause us to cease operations.
• We are a development stage company with a limited operating history, making it difficult for you to evaluate our business and your investment.
• If the FDA or comparable foreign regulatory authorities approve generic versions of any of our product candidates that receive marketing approval, or such authorities do not grant our products sufficient, or any, periods of exclusivity before approving generic versions of our products, the sales of our products could be adversely affected.
• If we fail to obtain or maintain Orphan Drug exclusivity for BIV201, we will have to rely on other potential marketing exclusivity, and on our intellectual property rights, which may reduce the length of time that we can prevent competitors from selling generic versions of BIV201.
• We will need to raise substantial additional capital in the future to fund our operations and we may be unable to raise such funds when needed and on acceptable terms, which could have a materially adverse effect on our business.

Legal proceedings

To our knowledge, other than described below, neither the Company nor any of its officers or directors is a party to any material legal proceeding or litigation and such persons know of no material legal proceeding or contemplated or threatened litigation, other than as described below. There are no judgments against us or our officers or directors. None of our officers or directors has been convicted of a felony or misdemeanor relating to securities or performance in corporate office.

The opening of Item 3, Legal Proceedings.⁴